Dermatology Medical News about Hidradenitis

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Hitting Chronic Lymphocytic Leukemia Where it Hurts

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Increased Serum Tumour Necrosis Factor- in Hidradenitis Suppurativa Patients: Is There a Basis for Treatment with Anti-Tumour Necrosis Factor- Agents
Acta Dermato-Venereologica, 10/29/09

Matusiak T et al. – Hidradenitis suppurativa (HS) is a recurrent, debilitating suppurative skin disease. Nowadays the major challenge is the choice of optimal treatment. Many conservative therapies seem to have only a supportive character and do not prevent progression of the disease. Early surgical intervention with complete excision of the involved areas is still considered to be the most efficient therapy, but anti–tumour necrosis factor (TNF)– agents may offer a possible non–surgical treatment.

<< Previous
Unique skin changes in a case of Albright hereditary...

Next >>
How sensitive is physician performance to alternative...